{"id":548032,"date":"2010-04-30T14:18:34","date_gmt":"2010-04-30T18:18:34","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=76871"},"modified":"2010-04-30T14:18:34","modified_gmt":"2010-04-30T18:18:34","slug":"idenix-raises-26-2m","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/548032","title":{"rendered":"Idenix Raises $26.2M"},"content":{"rendered":"\n
deals<\/a>, Biotech<\/a>, stock sale<\/a><\/div>\n

\t\tErin Kutz wrote:<\/strong><\/p>\n

Idenix Pharmaceuticals<\/a> (NASDAQ: IDIX<\/a>), a Cambridge, MA-based developer of anti-viral drugs, has priced an offering of 6.46 million shares of its common stock at $4.35 per share, an SEC filing<\/a> revealed. Thomas Weisel Partners is acting as the sole book-running manager of the deal, which will bring in net proceeds of about $26.2 million to Idenix, according to a company announcement<\/a>. The funding will go to general corporate purposes, research and development expenses, and potential acquisitions.<\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

\t \t\t\t
\n\t\t\t\t\t\t
\n\t\t\t
\n\t\t\t<\/a>
\n\t\t\t
\n\t\t\t\t

\n

\n\"\"<\/a>
\n\"\"<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

deals, Biotech, stock sale Erin Kutz wrote: Idenix Pharmaceuticals (NASDAQ: IDIX), a Cambridge, MA-based developer of anti-viral drugs, has priced an offering of 6.46 million shares of its common stock at $4.35 per share, an SEC filing revealed. Thomas Weisel Partners is acting as the sole book-running manager of the deal, which will bring in […]<\/p>\n","protected":false},"author":1661,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-548032","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/548032","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1661"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=548032"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/548032\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=548032"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=548032"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=548032"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}